ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,013.13
      -1.71%
      US Tech 100
      21,038.40
      -2.10%
      Dow Jones
      43,428.02
      -1.69%
      Brent Oil
      73.935
      0.00%
      Bitcoin
      96,195.22
      0.06%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Septerna Inc (SEPN) Quote

      Septerna Inc

      Septerna Inc (SEPN)

      NASDAQ
      5.80
      -0.09
      (-1.53%)
      Closed February 21 4:00PM
      Delayed by 15 minutes
      6.10
      0.30
      (5.17%)
      After Hours: 7:58PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      6.10
      Bid
      6.05
      Ask
      6.09
      Volume
      1,170,862
      5.641 Day's Range 6.2225
      4.49 52 Week Range 28.99
      Market Cap
      270.857M
      Previous Close
      5.89
      Open
      6.06
      Last Trade
      100
      @
      6.1
      (formt)
      Last Trade Time
      Financial Volume
      $ 6,856,679
      VWAP
      5.8561
      Average Volume (3m)
      506,179
      Shares Outstanding
      44,402,742
      Dividend Yield
      -
      PE Ratio
      61.85
      Earnings Per Share (EPS)
      0.09
      Revenue
      151k
      Net Profit
      4.18M

      About Septerna Inc

      Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the dis... Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Septerna Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SEPN. The last closing price for Septerna was $5.89. Over the last year, Septerna shares have traded in a share price range of $ 4.49 to $ 28.99.

      Septerna currently has 44,402,742 shares outstanding. The market capitalization of Septerna is $261.53 million. Septerna has a price to earnings ratio (PE ratio) of 61.85.

      Ask ADVFN Intelligence (AI)

      SEPN Latest News

      More News

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 18 2025
      SEPN (-1.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      January 06 2025
      SEPN (-1.53%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 20 2024
      SEPN (-1.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 20 2024
      SEPN (-1.53%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      October 28 2024
      SEPN (-1.53%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-5.9-49.16666666671213.194.4926301806.66151141CS
      4-12.13-66.538672517818.2319.024.497710568.85002638CS
      12-18.84-75.541299117924.9428.994.4950617915.45464325CS
      26-17.4-74.042553191523.528.994.4942787216.72811297CS
      52-17.4-74.042553191523.528.994.4942787216.72811297CS
      156-17.4-74.042553191523.528.994.4942787216.72811297CS
      260-17.4-74.042553191523.528.994.4942787216.72811297CS

      SEPN - Frequently Asked Questions (FAQ)

      What is the current Septerna share price?
      The current share price of Septerna is $ 6.10
      How many Septerna shares are in issue?
      Septerna has 44,402,742 shares in issue
      What is the market cap of Septerna?
      The market capitalisation of Septerna is USD 261.53M
      What is the 1 year trading range for Septerna share price?
      Septerna has traded in the range of $ 4.49 to $ 28.99 during the past year
      What is the PE ratio of Septerna?
      The price to earnings ratio of Septerna is 61.85
      What is the cash to sales ratio of Septerna?
      The cash to sales ratio of Septerna is 1.71k
      What is the reporting currency for Septerna?
      Septerna reports financial results in USD
      What is the latest annual turnover for Septerna?
      The latest annual turnover of Septerna is USD 151k
      What is the latest annual profit for Septerna?
      The latest annual profit of Septerna is USD 4.18M
      What is the registered address of Septerna?
      The registered address for Septerna is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
      Which industry sector does Septerna operate in?
      Septerna operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      BOXLBoxlight Corporation
      $ 3.1099
      (51.70%)
      		1.84M
      GDEVGDEV Inc
      $ 20.90
      (46.56%)
      		264.44k
      IVVDInvivyd Inc
      $ 1.7501
      (44.64%)
      		37.75M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      DOYUDouYu International Holdings Ltd
      $ 7.19
      (-55.31%)
      		1.28M
      MNDRMobile health Network Solutions
      $ 0.5048
      (-46.29%)
      		18.61M
      BLUEbluebird bio Inc
      $ 4.09
      (-41.90%)
      		5.44M
      FLDFold Holdings Inc
      $ 6.95
      (-37.39%)
      		488.54k
      GCLGCL Global Holdings Ltd
      $ 3.83
      (-31.48%)
      		635.26k
      MLGOMicroAlgo Inc
      $ 6.3767
      (454.50%)
      		531.54M
      UPCUniverse Pharmaceuticals Inc
      $ 0.2003
      (40.56%)
      		420.21M
      ADTXAditxt Inc
      $ 0.0922
      (-22.39%)
      		278.25M
      NVDANVIDIA Corporation
      $ 134.43
      (-4.05%)
      		228.14M
      HOLOMicroCloud Hologram Inc
      $ 1.565
      (31.51%)
      		190.81M

      Discussion

      View Full Feed
      Homebrew Homebrew 1 minute ago
      $420,000 salary even if he naps all day.
      QSEP
      OMOLIVES OMOLIVES 1 minute ago
      Should get some structuring news soon. It will be second quarter before you know it.
      DROR
      Investor082 Investor082 2 minutes ago
      LOL! So what you are saying is that NICE wont approve because it costs $50k to manufacture with manual method. But it will approve when it costs $25k to manufacture with Flaskworks?

      So they don't see the value in DCVAX-L at $50k manufacturing cost. That does not bode well for the pro
      NWBO
      IH Admin [Shelly] IH Admin [Shelly] 3 minutes ago
      Could be a possibility though I'd prob request Politics/Religion.

      And, yeah, the whole politics drama these days makes it difficult to know where the line is.
      ilovetech ilovetech 3 minutes ago
      @autologous_assassin on "X":
      Flaskworks' GMP approval could be a game-changer for cell therapy manufacturing, particularly for personalized therapies like $NWBO DCVax®-L. Here’s why:

      1. Cost Reduction and Scalability

      No Big Pharma (BP) has done this: Despite bil
      NWBO
      Quick Sand Quick Sand 4 minutes ago
      Mr Kyte will receive 35k per month and 1.5 million in bonuses ?????

      He better make good on that $20.00 share price 🤣
      QSEP
      IH Admin [Shelly] IH Admin [Shelly] 5 minutes ago
      No idea how many PMs you have in your inbox, but I recall someone in the past having never moved any PMs to Archive and there were several hundred. If that's you, then move them to Archive. There's even a handy button at the top that you says "Archive All". If you don't want to do that for whatev
      blackcat blackcat 6 minutes ago
      If they don't manage to stop him, there are going to be a lot of dead kids.
      blownaccount9 blownaccount9 6 minutes ago
      Lmao not sure how I’ve yet to block you. I block all “it’s a red day dam you shorts!” Posts. Cry more.
      FNMA
      blackhawks blackhawks 7 minutes ago
      But their constituents will.

      Not a single repulseklan congressperson will feel this pain. Not a single one.
      fuagf fuagf 7 minutes ago
      Yep. Trump no doubt an extreme sociopath and imo his Covid
      disgrace could possibly qualify him for the psychopathic camp.

      He likely knows the difference between right and wrong,
      still the borderline would be grey. Or orangey-gray.
      skitahoe skitahoe 7 minutes ago
      I'm not suggesting that they don't do the work, but why we're down is because they're not doing the required financial documentations. Until they get up to date on the quarterlies we'll be stuck where we are in spite of mega-factories, etc.

      Gary
      CRTG
      Louie_Louie Louie_Louie 8 minutes ago
      🤞🤞🤞up next: the Obama 11k docs
      https://www.foxnews.com/politics/bondi-says-epstein-client-list-sitting-my-desk-right-now-reviewing-jfk-mlk-files
      MasterBlastr MasterBlastr 9 minutes ago
      Do get some recommendations before you go. Downtown has changed a lot. For the worse.
      surfer44 surfer44 9 minutes ago
      The Real Story Behind Gold Shortages | Gold Crisis COVER-UP | Dave Kranzler

      https://youtu.be/4W94yHU46q0
      GOLD
      crowin crowin 10 minutes ago
      RDAR is a SCAM operated by an Italian

      So then RDAR is a foreign SCAM wanting Americas money!

      Up list to NASDAQ coming soon..........right?

      RDAR just put out some carrots on a stick recently, go read the recent PR


      No real meat her
      RDAR
      gfp927z gfp927z 11 minutes ago
      >>> The Fed's $16 Trillion Bailouts Under-Reported


      Forbes

      ByTracey Greenstein

      Sep 20, 2011


      https://www.forbes.com/sites/traceygreenstein/2011/09/20/the-feds-16-trillion-bailouts-under-reported/


      The med
      jhdf51 jhdf51 11 minutes ago
      No worries!

      JHD
      COOP

      Your Recent History

      NASDAQ
      SEPN
      Septerna
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads